Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590..
DOI: 10.3322/caac.21590
Herlemann A., Washington S.L., Cooperberg M.R. Health care delivery for metastatic hormone-sensitive prostate cancer across the globe. Eur Urol Focus. 2019;5(2):155–158. doi: 10.1016/j.euf.2018.12.003..
DOI: 10.1016/j.euf.2018.12.003
Гафанов Р.А. Гормональная и химиотерапия у больных гормончувствительным раком предстательной железы. Онкоурология. 2016;12(1):63–68. doi: 10.17650/1726-9776-2016-12-1-63-68..
DOI: 10.17650/1726-9776-2016-12-1-63-68
Павлов А.Ю., Гафанов Р.А., Цыбульский А.Д., Фастовец С.В., Кравцов И.Б. Современная стратегия лекарственной терапии метастатического и кастрационно-резистентного рака предстательной железы. РМЖ. 2016;(8):476–479. Режим доступа: https://www.rmj.ru/articles/urologiya/Sovremennaya_strategiya_lekarstvennoy_terapiimetastaticheskogo_i_kastracionno-rezistentnogo_raka_predstatelynoy_ghelezy.https://www.rmj.ru/articles/urologiya/Sovremennaya_strategiya_lekarstvennoy_terapiimetastaticheskogo_i_kastracionno-rezistentnogo_raka_predstatelynoy_ghelezy
Павлов А.Ю., Гафанов Р.А., Цыбульский А.Д., Фастовец С.В., Кравцов И.Б. Современная стратегия лекарственной терапии метастатического и кастрационно-резистентного рака предстательной железы. РМЖ. 2016;(8):476–479. Режим доступа: https://www.rmj.ru/articles/urologiya/Sovremennaya_strategiya_lekarstvennoy_terapiimetastaticheskogo_i_kastracionno-rezistentnogo_raka_predstatelynoy_ghelezy.https://www.rmj.ru/articles/urologiya/Sovremennaya_strategiya_lekarst-
Гафанов Р.А., Дзидзария А.Г., Кравцов И.Б., Фастовец С.В. Метастатический гормоночувствительный рак предстательной железы: практические рекомендации и оптимизация выбора терапии. Онкоурология. 2018;14(4):139–149. doi: 10.17650/1726-9776-2018-14-4-139–149..
DOI: 10.17650/1726-9776-2018-14-4-139–149
Гафанов Р.А., Дзидзария А.Г., Кравцов И.Б., Фастовец С.В. Метастатический гормоночувствительный рак предстательной железы: практические рекомендации и оптимизация выбора терапии. Онкоурология. 2018;14(4):139–149. doi: 10.17650/1726-9776-2018-14-4-139–149..
DOI: 10.17650/1726-9776-2018-14-4-139-149
Харченко В.П., Каприн А.Д., Гафанов Р.А., Костин А.А. Гормонорезистентный рак предстательной железы. Возможности лечения. Андрология и генитальная хирургия. 2001;2(4):8–12.
Харченко В.П., Каприн А.Д., Гафанов Р.А., Костин А.А., Подшивалов А.В. Химиотерапия гормонорезистентного рака простаты. В: Тезисы I конгресса профессиональной асссоциации андрологов России. Кисловодск; 2001. С. 35–36.
Lee D.J., Mallin K., Graves A.J., Chang S.S., Penson D.F., Resnick M.J., Barocas D.A. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198(6):1230–1240. doi: 10.1016/j.juro.2017.05.074..
DOI: 10.1016/j.juro.2017.05.074
Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. doi: 10.1016/S1470-2045(12)70560-0..
DOI: 10.1016/S1470-2045(12)70560-0
Gravis G., Boher J.M., Joly F., Soulié M., Laurence Albiges L., Priou F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–262. doi: 10.1016/j.eururo.2015.11.005..
DOI: 10.1016/j.eururo.2015.11.005
Gravis G., Boher J.M., Joly F., Soulié M., Laurence Albiges L., Priou F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–262. doi: 10.1016/j.eururo.2015.11.005..
DOI: 10.1016/j. eururo.2015.11.005
Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746. doi: 10.1056/NEJMoa1503747..
DOI: 10.1056/NEJMoa1503747
Eisenberger M., Crawford E., Wolf M., Blumenstein B., McLeod D., Benson R. et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 1994;21(5):613–619. Available at: https://pubmed.ncbi.nlm.nih.gov/7939752.https://pubmed.ncbi.nlm.nih.gov/7939752
Eisenberger M., Crawford E., Wolf M., Blumenstein B., McLeod D., Benson R. et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 1994;21(5):613–619. Available at: https://pubmed.ncbi.nlm.nih.gov/7939752.https://pubmed.ncbi.nlm.nih.gov/7939752
Kyriakopoulos C.E., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. J Clin Oncol. 2018;36(11):1080–1087. doi: 10.1200/JCO.2017.75.3657..
DOI: 10.1200/JCO.2017.75.3657
Gravis G., Boher J.M., Chen Y.H., Liu G., Fizazi K., Carducci M.A. et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018;73(6):847–855. doi: 10.1016/j.eururo.2018.02.001..
DOI: 10.1016/j.eururo.2018.02.001
James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177. doi: 10.1016/S0140-6736(15)01037-5..
DOI: 10.1016/S0140-6736(15)01037-5
Clarke N., Ali A., Ingleby F.C., Hoyle A., Amos C.L., Attard G. et al. Addition of docetaxel to hormonal therapy in lowand high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992–2003. doi: 10.1093/annonc/mdz396..
DOI: 10.1093/annonc/mdz396
Templeton A.J., Vera-Badillo F.E., Wang L., Attalla M., De Gouveia P., Leibowitz-Amit R. et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol. 2013;24(12):2972–2977. doi: 10.1093/annonc/mdt397..
DOI: 10.1093/annonc/mdt397
James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi: 10.1056/NEJMoa1702900..
DOI: 10.1056/NEJMoa1702900
Becker P.S., Griffiths E.A., Alwan L.M., Bachiashvili K., Brown A., Cool R. et al. NCCN guidelines insights: hematopoietic growth factors, version 1.2020. J Natl Compr Canc Netw. 2020;18(1):12–22. doi: 10.6004/jnccn.2020.0002..
DOI: 10.6004/jnccn.2020.0002
Rush H., Cook A.D., Brawley C.D., Murphy L., Macnair A., Millman R. et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. J Clin Oncol. 2020;38(6S). doi: 10.1200/jco.2020.38.6_suppl.14..
DOI: 10.1200/jco.2020.38.6_suppl.14
Bumbaca B., Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharm Sin B. 2018;8(4):518–529. doi: 10.1016/j.apsb.2018.04.007..
DOI: 10.1016/j.apsb.2018.04.007
Mahon K.L., Qu W., Lin H.M., Spielman C., Cain D., Jacobs C. et al. Serum free methylated glutathione S-transferase 1 DNA levels, survival, and response to docetaxel in metastatic, castration-resistant prostate cancer: post hoc analyses of data from a phase 3 trial. Eur Urol. 2019;76(3):306– 312. doi: 10.1016/j.eururo.2018.11.001..
DOI: 10.1016/j.eururo.2018.11.001
Mahon K., Lin H., Lee-Ng M., Cain D., Jacobs C., Stockler M. et al. Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(7S). doi: 10.1200/jco.2019.37.7_suppl.230..
DOI: 10.1200/jco.2019.37.7_suppl.230
Choueiri T.K., Xie W., D’Amico A.V., Ross R.W., Hu J.C., Pomerantz M. et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009;115(5):981– 987. doi: 10.1002/cncr.24064..
DOI: 10.1002/cncr.24064
Flanagan J., Kathryn Gray P., Hahn N., Hayes J., Myers L.J., Carney- Doebbeling C., Sweeney C.J. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011;22(4):801–807. doi: 10.1093/annonc/mdq443..
DOI: 10.1093/annonc/mdq443
Sharma J., Gray K.P., Evan C., Nakabayashi M., Fichorova R., Rider J. et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014;74(3):225–234. doi: 10.1002/pros.22744..
DOI: 10.1002/pros.22744
Zhao S.G., Laura Chang S.L., Erho N., Yu M., Lehrer J., Alshalalfa M. et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3(12):1663–1672. doi: 10.1001/jamaoncol.2017.0751..
DOI: 10.1001/jamaoncol.2017.0751
Hamid A., Wang X.V., Chen Y.H., Feng F.Y., Benjamin Den R., Attard G. et al. Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): a correlative study of E3805 CHAARTED. J Clin Oncol. 2020;38(6S):160– 162. doi: 10.1200/jco.2020.38.6_suppl.162..
DOI: 10.1200/jco.2020.38.6_suppl.162
Gillessen S., Attard G., Beer T.M., Beltran H., Bossi A., Bristow R. et al. Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2):178–211. doi: 10.1016/j.eururo.2017.06.002..
DOI: 10.1016/j.eururo.2017.06.002
Mohler J.L., Antonarakis E.S., Armstrong A.J., D’Amico A.V., Davis B.J., Dorff T. et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505. doi: 10.6004/jnccn.2019.0023..
DOI: 10.6004/jnccn.2019.0023
Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479. doi: 10.1016/j.eururo.2013.11.002..
DOI: 10.1016/j.eururo.2013.11.002
Fizazi K., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B.Y. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi: 10.1056/NEJMoa1704174..
DOI: 10.1056/NEJMoa1704174
Davis I.D., Martin A.J., Stockler M.R., Begbie S., Chi K.N., Chowdhury S. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131. doi: 10.1056/NEJMoa1903835..
DOI: 10.1056/NEJMoa1903835
Armstrong A., Szmulewitz R., Petrylak D., Villers A., Azad A., Alcaraz A. et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial. J Clin Oncol. 2019;37(7):687. doi: 10.1200/JCO.2019.37.7_suppl.687..
DOI: 10.1200/JCO.2019.37.7_suppl.687
Chi K.N., Agarwal N., Bjartell A., Chung B.H., Pereira de Santana Gomes A.J., Given G. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;38(1)1:13–24. doi: 10.1056/NEJMoa1903307..
DOI: 10.1056/NEJMoa1903307
Armstrong A.J., Szmulewitz R.Z., Petrylak D.P., Holzbeierlein J., Villers A., Azad A. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986. doi: 10.1200/JCO.19.00799..
DOI: 10.1200/JCO.19.00799
Agarwal N., Chowdhury S., Bjartell A., Chung B., Gomes A., Given R. et al. Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane). J Clin Oncol. 2020;38(6 Suppl.):82–89. doi: 10.1200/JCO.2020.38.6_suppl.82..
DOI: 10.1200/JCO.2020.38.6_suppl.82
Gillessen S., Attard G., Beer T.M., Beltran H., Bjartell A., Bossi A. et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77(4):508–547. doi: 10.1016/j.eururo.2020.01.012..
DOI: 10.1016/j.eururo.2020.01.012
Lu-Yao G., Nikita N., Keith S.W., Nightingale G., Gandhi K., Hegarty S.E. et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77(2):158–166. doi: 10.1016/j.eururo.2019.07.031..
DOI: 10.1016/j.eururo.2019.07.031
Khalaf D.J., Sunderland K., Eigl B.J., Kollmannsberger C.K., Ivanov N., Finch D.L. et al. Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial. Eur Urol. 2019;75(6):940–947. doi: 10.1016/j.eururo.2018.12.015..
DOI: 10.1016/j.eururo.2018.12.015
Penson D.F. Keynote: Financial toxicity and quality of life: understanding and improving patientcentered outcomes in genitourinary malignancies. Available at: https://meetinglibrary.asco.org/record/180842/video.https://meetinglibrary.asco.org/record/180842/video
Penson D.F. Keynote: Financial toxicity and quality of life: understanding and improving patientcentered outcomes in genitourinary malignancies. Available at: https://meetinglibrary.asco.org/record/180842/video.https://meetinglibrary.asco.org/record/180842/video
Parker C., James N., Brawley C., Clarke N., Hoyle A., Ali A. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–2366. doi: 10.1016/S0140-6736(18)32486-3..
DOI: 10.1016/S0140-6736(18)32486-3
Halabi S. Subgroup analysis in clinical trials. Paper presented at: Advanced Prostate Cancer Consensus Conference; August 2019; Basel, Switzerland. Available at: https://www.urotoday.com/conference-highlights/apccc-2019/114634-apccc-2019-subgroup-analysis-of-mcrpc-trials.html.https://www.urotoday.com/conference-highlights/apccc-2019/114634-apccc-2019-subgroup-analysis-of-mcrpc-trials.html
Halabi S. Subgroup analysis in clinical trials. Paper presented at: Advanced Prostate Cancer Consensus Conference; August 2019; Basel, Switzerland. Available at: https://www.urotoday.com/conference-highlights/apccc-2019/114634-apccc-2019-subgroup-analysis-of-mcrpc-trials.html.https://www.urotoday.com/conference-highlights/apccc-2019/114634-apccc-2019-subgroup-analysis-of-mcrpc-trials.html
Attard G., Borre M., Gurney H., Loriot Y., Andresen-Daniil C., Kalleda R. et al. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018;36(25):2639–2646. doi: 10.1200/JCO.2018.77.9827..
DOI: 10.1200/JCO.2018.77.9827
Khalaf D., Annala M., Finch D.L., Oja C.D., Vergidis J., Zulfiqar M. et al. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): results for 2nd-line therapy. J Clin Oncol. 2018;36(15S):5015. doi: 10.1200/JCO.2018.36.15_suppl.5015..
DOI: 10.1200/JCO.2018.36.15_suppl.5015
Smith M.R., Saad F., Rathkopf D.E., Mulders P.F.A., de Bono J.S., Small E.J. et al. Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;72(1):10–13. doi: 10.1016/j.eururo.2017.03.007..
DOI: 10.1016/j.eururo.2017.03.007
Zhang T., Dhawan M.S., Healy P., George D.J., Harrison M.R., Oldan J. et al. Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(4):392–399. doi: 10.1016/j.clgc.2015.01.004..
DOI: 10.1016/j.clgc.2015.01.004
Azad A.A., Eigl B.J., Murray R.N., Kollmannsberger C., Chi K.N. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67(1):23–29. doi: 10.1016/j.eururo.2014.06.045..
DOI: 10.1016/j.eururo.2014.06.045
de Wit R., de Bono J., Sternberg C.N., Fizazi K., Tombal B., Wülfing C. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506–2518. doi: 10.1056/NEJMoa1911206..
DOI: 10.1056/NEJMoa1911206
de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147– 1154. doi: 10.1016/S0140-6736(10)61389-X..
DOI: 10.1016/S0140-6736(10)61389-X
de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147– 1154. doi: 10.1016/S0140-6736(10)61389-X..
DOI: 10.1016/ S0140-6736(10)61389-X
Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi: 10.1056/NEJMoa1405095..
DOI: 10.1056/NEJMoa1405095
Алексеев Б.Я., Матвеев В.Б., Русаков И.Г., Волкова М.И., Карякин О.Б., Болотина Л.В. и др. Резолюция по итогам Совещания экспертов по лечению кастрационно-резистентного рака предстательной железы. Онкоурология. 2016;12(3):109–110. doi: 10.17650/1726-9776-2016-12-3-109-110..
DOI: 10.17650/1726-9776-2016-12-3-109-110
Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506..
DOI: 10.1056/NEJMoa1207506
de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi: 10.1056/NEJMoa1014618..
DOI: 10.1056/NEJMoa1014618
Ryan C.J., Smith M.R., Fizazi K., Saad F., Mulders P.F., Sternberg C.N. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152– 160. doi: 10.1016/S1470-2045(14)71205-7..
DOI: 10.1016/S1470-2045(14)71205-7